bluebird bio, Inc. Class Action Lawsuit - BLUE

According to the complaint, on December 8, 2023, Blue announced that the Food and Drug Administration (FDA) approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs). However, the Lyfgenia approval came with a black box warning for haematological malignancies after two patients developed AML during the clinical trials. Analysts noted that they did not expect the black box warning or the absence of a priority review voucher. Following this news, Blue’s stock price fell by $1.95 per share, or approximately 40% to close at $2.86 per share.

In order to be eligible to join the BLUE class action lawsuit, you must have incurred a loss on shares of bluebird bio purchased during the class period listed above.

If you suffered a loss in bluebird bio during the relevant time frame or pursuant to the relevant offering(s), you have until May 28, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.